today, dfb continues to invest in identifying and solving critical unmet medical needs.business successesdpt laboratories: contract development and manufacturing organization (cdmo) of sterile and nonsterile liquid and semi-solid pharmaceuticals1990 – acquired dermatological products of texas from alcon, renamed it dpt laboratories2012 – sold a majority interest to renaissance pharmaceuticals, a portfolio company of roundtable healthcare partners2016 – sale of nonsterile, dermatology-focused division by renaissance to mylanhealthpoint biotherapeutics: the leading pharmaceutical company in wound care with the largest selling drug and a strong r&d pipeline including a phase iii biologic1992 – founded by dfb pharmaceuticals2006 - acquired santyl® and grew it to the leading pharmaceutical in wound care2012 – sold to smith & nephew as the basis for its biotherapeutics platformcoria laboratories: dermatology company with a portfolio of drug and otc products1994 – founded as a division of healthpoint2001 – established as a separate company, coria laboratories2008 – sold to valeant pharmaceuticals as its initial acquisition into dermatologyhealthpoint surgical: developed and commercialized a portfolio of surgical antisepsis technologies2003 – established as a separate division by healthpoint2010 – licensed usa marketing rights for surgicept® and triseptin® to carefusion (now becton dickinson)2011 – licensed usa marketing rights for aldahol® to olympus2017 – established a manufacturing and distribution relationship in chinaphyton biotech: oncology api development and manufacturing via plant cell fermentation (pcf®)2003 – acquired phyton, which included an exclusive long-term supply relationship with bms supplying pcf® paclitaxel intermediate for its taxol® paclitaxel injection, the first taxane approved for oncology2012 – launched its own commercial oncology api business selling paclitaxel and docetaxel api's on a global basis2014 – expanded development services via pcf® for plant-derived pharmaceuticals2018 – captured several high profile development opportunities in europe and china including grant from the bill & melinda gates foundation2021 – received regulatory approval from china’s nmpa for its plant cell fermentation-derived paclitaxel active pharmaceutical ingredient2022 – continues to expand its capabilities around plant cell and specialty fermentation solutions and its broad application to pharmaceuticals, food ingredients, cosmetics, and traditional chinese herbal medicines